齐鲁晚报·齐鲁壹点记者尹睿 魏银科 74%商品实现零关税、47大类免税商品扩容、双15%税收优惠、30%本地增值免关税......2025年12月18日，海南全岛封关运作将正式启动。作为我国自贸港 建设的里程碑事件，封关不仅将重塑海南的政策格局，更将释放涵盖消费、产业、贸易的多重红利。16日晚，记者抵达海口，实地探访封关前夕的热潮与 变革。 海口氛围拉满，免税店掀起"封关前消费热" 12月17日，海口沉浸在全岛封关运作前最后的倒计时氛围中，从空中门户到城市街巷，历史性时刻的期待感扑面而来。 在海口美兰国际机场，出港通道两侧、核心区域的电子大屏乃至悬挂的条幅，无不醒目地标注着"2025年12月18日 海南自贸港 全岛封关 正式启动"的标 语，让每一位抵达的旅客都直观感受到历史性时刻的临近。 市区里的氛围同样浓厚。在海口市骑楼老街北门广场，一块显示"距离海南自由贸易港封关运作还有01天"的巨型倒计时牌，成为市民游客争相打卡的焦 点。"我们是从湖北武汉来，先在海口玩两天，等18号封关后再去免税店逛逛。"游客李女士笑着说，她特意将免税购物安排在了封关之后，期待体验新政 带来的变化。像李女士一样抱有期待的游客不在少数， ...

Market Overview - Wall Street experienced mixed performance last week, with the S&P 500 down 0.6%, the Dow Jones up 1.1%, and the Nasdaq down approximately 1.6% [1] - Tech stocks faced significant pressure, impacting the Nasdaq-100 and S&P 500, with Roundhill Magnificent Seven ETF (MAGS) down 1.7% and State Street Technology Select Sector SPDR ETF (XLK) down 2.5% [1] Tech Sector Performance - Oracle's shares fell 14% due to revenue misses, negatively affecting related AI companies like NVIDIA and Micron [2] - Broadcom's stock dropped about 11% despite strong earnings, raising concerns over high capital expenditures and delayed AI revenue realization [2] Federal Reserve Actions - The Federal Reserve implemented its final rate cut of the year, lowering the benchmark federal funds rate to a range of 3.5% to 3.75% following a divided vote [3] - The Fed's outlook for 2026 appears more cautious, projecting only one rate cut next year, consistent with previous forecasts [4] Winning ETF Areas - **Cannabis Sector**: Roundhill Cannabis ETF (WEED) rose 51.2% and Amplify Seymour Cannabis ETF (CNBS) increased 51.0% due to speculation about potential easing of federal marijuana regulations [5] - **Silver Miners**: Global X Silver Miners ETF (SIL) gained 8.4% and Amplify Junior Silver Miners ETF (SILJ) rose 7.6% driven by increased industrial demand and supply shortages [6] - **Space Economy**: Procure Space ETF (UFO) increased by 7.8%, with Rocket Lab Corp (RKLB) surging 22.8% due to heightened investor interest in the space sector [7] - **Gold Miners**: VanEck Junior Gold Miners ETF (GDXJ) rose 7.1%, and SPDR Gold Trust (GLD) gained 2.2% as the U.S. dollar weakened [9] - **Platinum**: GraniteShares Platinum Trust (PLTM) increased by 6.3%, with platinum prices surpassing $1,700 per ounce amid projected market deficits [10] - **Health Care**: Roundhill GLP-1 & Weight Loss ETF (OZEM) rose 6.3%, being the first actively-managed GLP-1 ETF, highlighting advancements in weight loss pharmaceuticals [11]

NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding, the data from the vehicle-controlled Phase 1b proof-of-concept study did not show differentiation between SGT-210 and vehicle on the study’s ...

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large global pharm ...

Core Insights - Viatris Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9 a.m. PT / 12 p.m. ET [1] - A live webcast of the presentation will be available, along with an archived version for a limited time [2] Company Overview - Viatris is a global healthcare company that bridges the gap between generics and brand-name medications, aiming to address healthcare needs worldwide [3] - The company provides access to high-quality medicines for approximately 1 billion patients annually, covering a wide range of health conditions from birth to end-of-life care [3] - Viatris has a diverse portfolio of medicines and a unique global supply chain, with headquarters in the U.S. and global centers in Pittsburgh, Shanghai, and Hyderabad [3]

Core Insights - Merck announced positive topline results from the Phase 3 KEYNOTE-B15 trial for patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy [1] - The trial evaluated the combination of KEYTRUDA® (pembrolizumab) and Padcev® (enfortumab vedotin-ejfv) as neoadjuvant and adjuvant treatment, showing statistically significant results [1] Company Summary - Merck, known as MSD outside the United States and Canada, is focusing on innovative cancer treatments [1] - The positive results from the KEYNOTE-B15 trial may enhance Merck's position in the oncology market [1] Industry Summary - The trial results contribute to the growing body of evidence supporting immunotherapy and targeted therapy combinations in treating bladder cancer [1] - The findings may influence treatment protocols and patient outcomes in the field of oncology [1]

Core Insights - Astellas Pharma and Pfizer announced positive topline results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda, showing significant improvements in event-free survival and overall survival for muscle-invasive bladder cancer patients [1][5][7] Company Insights - Astellas Pharma is focused on advancing treatment options for muscle-invasive bladder cancer, with recent findings reinforcing the potential of PADCEV plus pembrolizumab to improve survival outcomes for a broad patient population [4][5] - Pfizer emphasizes the significance of the EV-304 results, indicating a potential shift in the standard of care for muscle-invasive bladder cancer patients, particularly those ineligible for platinum-based chemotherapy [5][6] Industry Insights - Muscle-invasive bladder cancer is a significant health concern, with nearly half of patients progressing to metastatic disease within three years of diagnosis, highlighting the need for effective treatment options [3][6] - The EV-304 trial results may lead to a new standard of care in bladder cancer treatment, moving away from conventional platinum-based chemotherapy [5][7]

Market Overview - The U.S. stock market is experiencing a decline, with the S&P 500 down 0.4% and the Dow Jones Industrial Average down 271 points or 0.6% as of 1:53 p.m. Eastern time, while the Nasdaq composite remains mostly unchanged [1] - Treasury yields have eased slightly after an initial drop, with the 10-year Treasury yield falling to 4.16% from 4.18% and the two-year Treasury yield easing to 3.48% from 3.51% [6] Economic Data - Recent mixed economic data has created uncertainty regarding future interest rate movements, with the U.S. unemployment rate reported at its worst level since 2021, but job additions exceeding economists' expectations [2][3] - A report indicated that revenue growth for U.S. retailers in October was stronger than anticipated, suggesting underlying economic strength [2] Inflation and Price Pressures - A report released indicated that average selling prices for businesses are rising sharply, with one of the fastest rates since mid-2022, while overall business activity growth has slowed to its weakest level since June [5] - Higher prices are being attributed to tariffs, affecting both manufacturing and services sectors, leading to broader affordability issues [6] Company-Specific Developments - Oracle's stock rose 2.4% and Broadcom's by 0.1%, despite previous sharp losses, as both companies reported stronger-than-expected quarterly profits [7] - CoreWeave, which provides access to AI chips, saw a decline of 4.9%, raising questions about the profitability of current AI technology investments [8] - Pfizer's stock fell 5.2% after providing a profit forecast for 2026 that was below analysts' expectations, although its revenue forecast for next year aligns closely with expectations [8] - Kraft Heinz's stock fell 0.1% following the announcement of Steve Cahillane as the new CEO, effective January 1, as the company prepares to split into two entities by the second half of 2026 [9] Global Market Trends - Stock markets in Europe and Asia experienced declines, with Japan's Nikkei 225 dropping 1.6% ahead of an anticipated interest rate hike by the Bank of Japan [10] - South Korea's Kospi fell 2.2%, while indexes in Hong Kong and Shanghai dropped by 1.5% and 1.1%, respectively [10]

Dow futures were up about 0.07% near 48,514. S&P 500 futures gained roughly 0.13% to 6,865, while Nasdaq futures rose 0.15% to around 25,419. The muted move reflects a market trying to balance softer economic signals with hopes that the Fed may be nearing the end of its tightening cycle. Tuesday’s regular session ended mixed. The Dow fell 0.62% and the S&P 500 slipped 0.24%, extending their losing streaks to three days. The Nasdaq Composite, however, managed a 0.23% gain, snapping its recent slide as inves ...

Core Insights - BioNxt Solutions Inc. is addressing the significant issue of dysphagia, which affects up to 40% of adults and is particularly prevalent in autoimmune disease patients, impacting treatment adherence and therapeutic success [1][3][7] - The company has developed a proprietary rapid-dissolving thin-film drug delivery platform, recently securing its first national patent, which is a crucial step towards commercialization in high-value autoimmune markets [2][8] Market Opportunity - The global market for Multiple Sclerosis (MS) drugs is projected to reach approximately USD 40-45 billion by 2033, while the Myasthenia Gravis (MG) treatment market is expected to grow to between USD 2.7-4.7 billion by 2032 [4] - BioNxt's thin-film technology offers a swallow-free and needle-free alternative, addressing the challenges posed by large tablets and injectable therapies for autoimmune patients [5][6] Product Development - The thin film formulation melts rapidly under the tongue, allowing for improved absorption and bioavailability, which is particularly beneficial for chronic autoimmune conditions [6][11] - BioNxt has completed GMP clinical batch manufacturing for its product BNT23001 and is preparing for a comparative human bioequivalence study in early 2026, anticipating an accelerated regulatory pathway due to the existing approval of cladribine tablets [9][10] Intellectual Property and Scalability - The newly granted Eurasian patent for BNT23001 protects a proprietary sublingual cladribine film, covering over 200 million people across eight member states, and is part of BioNxt's expanding global IP estate [8][11] - The company's thin-film technology is designed to be scalable, allowing for the reformulation of multiple approved drugs across various autoimmune and chronic disease markets, projected to exceed USD 75-80 billion annually over the next decade [11][13] Industry Trends - The oral transmucosal drug-delivery market is expected to grow from approximately USD 45.8 billion in 2025 to nearly USD 96.8 billion by 2033, indicating a shift towards patient-friendly drug delivery formats [13]